1. Acute toxicity and patient‐reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer
- Author
-
Masashi Mizumoto, Daichi Takizawa, Keiichi Tanaka, Toshiyuki Okumura, Hitoshi Ishikawa, Takashi Iizumi, Kei Nakai, Hideyuki Sakurai, Hirokazu Makishima, Haruko Numajiri, and Yuta Sekino
- Subjects
Male ,Oncology ,medicine.medical_specialty ,urologic and male genital diseases ,Androgen deprivation therapy ,Prostate cancer ,Quality of life ,Internal medicine ,Proton Therapy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Patient Reported Outcome Measures ,Adverse effect ,Proton therapy ,Radiological and Ultrasound Technology ,Genitourinary system ,business.industry ,Prostatic Neoplasms ,Androgen Antagonists ,medicine.disease ,Acute toxicity ,Treatment Outcome ,Quality of Life ,International Prostate Symptom Score ,business - Abstract
INTRODUCTION To confirm the feasibility of hypofractionated proton beam therapy (PBT), we compared the acute adverse event rates and International Prostate Symptom Score (IPSS) in prostate cancer patients treated with hypofractionated versus conventionally fractionated (2.0 Gy relative biological effectiveness (RBE)/fraction) PBT. METHODS We reviewed 289 patients with prostate cancer, of whom 73, 100, and 116 patients were treated with 2.0, 2.5, and 3.0 Gy (RBE)/fraction, respectively. The endpoints were acute genitourinary and gastrointestinal toxicities and the IPSS, evaluated up to 6 months after PBT initiation. RESULTS No significant differences were found in acute toxicity rates or the IPSS among the fractionation schedules. Diabetes mellitus, age, and androgen deprivation therapy were not identified as factors associated with the IPSS. CONCLUSION There were no significant differences in adverse events or quality of life among the three fractionation schedules early after PBT.
- Published
- 2021
- Full Text
- View/download PDF